Business Standard

Wockhardt Ltd News

Pharma shares shine; Dr Reddy's, FDC, Glenmark, Suven trade at record highs

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Pharma shares shine; Dr Reddy's, FDC, Glenmark, Suven trade at record highs
Updated On : 03 Jul 2024 | 2:57 PM IST

SmallCap index hits new peak; Roto, Atul Auto, Wockhardt zoom up to 19%

At 11:34 AM, the SmallCap index was up 1.33 per cent, outperforming the BSE Sensex and BSE Midcap indices

SmallCap index hits new peak; Roto, Atul Auto, Wockhardt zoom up to 19%
Updated On : 01 Jul 2024 | 11:56 AM IST

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end
Updated On : 28 Jun 2024 | 8:07 PM IST

Wockhardt Q4 results: Net loss at Rs 177 cr, revenue rises to Rs 700 cr

Drug firm Wockhardt on Tuesday reported a consolidated net loss of Rs 177 crore for the fourth quarter ended March 31, 2024. The company had reported a net loss of Rs 237 crore in the January-March quarter of 2022-23. Revenue from operations stood at Rs 700 crore for the period under review as compared with Rs 678 crore in the same period of FY23, the Mumbai-based drugmaker said in a regulatory filing. For the year ended March 31, 2024, the company reported a net loss of Rs 472 crore against a net loss of Rs 621 crore in 2022-23 fiscal. Revenue from operations increased to Rs 2,798 crore in FY24 compared with Rs 2,651 crore in FY23. The company said its board approved the re-appointment of Habil Khorakiwala as Executive Chairman for a further term of five years with effect from March 1, 2025, to February 28, 2030. Shares of the company on Tuesday ended 0.49 per cent down at Rs 557.95 apiece on the BSE.

Wockhardt Q4 results: Net loss at Rs 177 cr, revenue rises to Rs 700 cr
Updated On : 28 May 2024 | 11:28 PM IST

Wockhardt Hospitals launches early recovery program for liver transplant

The hospital group also claims that the ERP program improves the survival rate of the patients by approximately 2-3 per cent while enhancing patient outcomes through advanced techniques

Wockhardt Hospitals launches early recovery program for liver transplant
Updated On : 02 May 2024 | 8:21 PM IST

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally
Updated On : 14 Feb 2024 | 3:39 PM IST